Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...

Addison Shea's research project involving Bowhead whales earns place in weeklong STEM competition for more than $1.8 million ...

Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

News of a significant earnings beat propelled Regeneron Pharmaceuticals (NASDAQ: REGN) to a nearly 5% share price gain on the ...

Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase 2a trial – - Data presented at AACR 2023 supports ...

Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...

REGN reports better-than-expected Q4 results. However, lead drug Eylea sales decline in the United States due to competition.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its target price lowered by equities researchers at Bernstein Bank from $1,070.00 to $1,000.00 in a research note issued to investors on ...

Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its target price decreased by equities research analysts at Leerink Partners from $980.00 to $862.00 in a research note issued on Tuesday.